HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Every estradiol molecule that circulates in the body will eventually be metabolized. The first enzymatic step in that process — Phase 1 hydroxylation — isn't uniform. Two cytochrome P450 enzymes, CYP1A1 and CYP1B1, compete for the same estrogen substrate and route it toward two very different metabolic fates. CYP1A1 preferentially produces 2-hydroxyestradiol (2-OHE2), a relatively inert catechol estrogen with weak receptor activity. CYP1B1 preferentially produces 4-hydroxyestradiol (4-OHE2), a more reactive intermediate with greater genotoxic potential if not rapidly cleared. The ratio of these two metabolites — shaped substantially by your CYP1A1 and CYP1B1 genotypes — is one of the most important variables in the estrogen metabolism picture. The PlexusDx Precision Peptide Genetic Test analyzes key variants in both genes as part of 14 pathways, 49 peptides, and 150+ genetic insights — mapping your Phase 1 estrogen hydroxylation profile within the full Reproductive Health pathway.

Phase 1 Estrogen Metabolism: What CYP1A1 and CYP1B1 Actually Do

In the broader estrogen clearance sequence, Phase 1 is the hydroxylation step — the enzymatic modification that converts estradiol into catechol estrogen intermediates. These intermediates are more water-soluble than estradiol itself, but they are biologically active and chemically reactive. They must be rapidly inactivated by Phase 2 enzymes before excretion. Phase 1 doesn't clear estrogen; it transforms it into the form Phase 2 can clear.

Both CYP1A1 and CYP1B1 belong to the cytochrome P450 superfamily — a large class of oxidative enzymes involved in metabolizing endogenous hormones, xenobiotics, and medications. In estrogen metabolism specifically:

CYP1A1 is expressed primarily in extrahepatic tissues including lung, gastrointestinal tract, and peripheral tissues. It hydroxylates estradiol predominantly at the C-2 position, yielding 2-OHE2. 2-OHE2 has weak estrogenic activity — it binds estrogen receptors with lower affinity than estradiol itself, and in some contexts shows antiestrogenic properties by competing with estradiol for receptor binding without generating as strong a downstream signal. Its production is generally considered the more favorable Phase 1 route.

CYP1B1 is expressed in steroidogenic and reproductive tissues including ovary, uterus, breast, and adrenal gland, as well as many other tissues. It hydroxylates estradiol predominantly at the C-4 position, yielding 4-OHE2. 4-OHE2 is more estrogenically active than 2-OHE2 — it binds estrogen receptors with closer to full affinity — and, critically, it has a higher propensity to undergo further oxidation to 4-hydroxyestradiol semiquinones and quinones. These reactive species can form covalent DNA adducts if not neutralized by Phase 2 enzymes, particularly COMT-mediated methylation and glutathione conjugation by GSTM1/GSTT1.

The balance of CYP1A1 and CYP1B1 activity — and therefore the 2-OHE2:4-OHE2 ratio — is substantially shaped by the genetic variants each woman carries in these two genes.

Key CYP1A1 Variants and Their Functional Effects

CYP1A1 carries several well-characterized polymorphisms studied across multiple populations and biological contexts:

CYP1A1 MspI (rs4646903, T6235C) — located in the 3' untranslated region. The C allele (variant) is associated with higher inducibility of CYP1A1 expression in some tissues. Carriers of the variant allele may show increased CYP1A1 transcription in response to certain inducers, potentially shifting more estradiol toward the 2-OHE2 pathway under induction conditions. This variant has been studied across multiple published association studies in estrogen-sensitive tissue contexts.

CYP1A1 Ile462Val (rs1048943, A4889G) — a coding variant in exon 7 that substitutes isoleucine for valine at position 462 of the heme-binding region. The Val (462Val) allele is associated with increased enzyme activity — the enzyme variant shows higher catalytic efficiency for estradiol hydroxylation in vitro. Women carrying the high-activity Val allele have a genetically elevated tendency toward CYP1A1-mediated 2-OHE2 production. This variant is more commonly studied in Asian populations, where allele frequencies are higher than in European populations.

Functionally, higher CYP1A1 activity tilts Phase 1 metabolism toward the 2-hydroxylation route — producing more 2-OHE2 from a given estradiol substrate. Because 2-OHE2 is less estrogenically active and has a more favorable clearance profile, higher CYP1A1 activity relative to CYP1B1 activity is generally associated with a more favorable estrogen metabolite ratio.

Key CYP1B1 Variants and Their Functional Effects

CYP1B1 is highly polymorphic, with several variants demonstrating documented functional consequences for 4-OHE2 production:

CYP1B1 Ala119Val (rs10012, C142G) — a coding variant in exon 2. The Val (119Val) allele has been associated with modestly increased CYP1B1 enzyme activity in some functional studies. Higher-activity CYP1B1 Ala119Val variants shift the equilibrium toward greater 4-hydroxylation of estradiol — producing more 4-OHE2 per unit of estrogen substrate.

CYP1B1 Leu432Val (rs1056836, C1294G) — a coding variant in exon 3, substituting leucine for valine at position 432. This is the most studied CYP1B1 variant in the estrogen biology literature. The Val (432Val) allele is associated with higher enzyme activity and higher 4-OHE2 production relative to the Leu allele. Val/Val homozygotes at Leu432Val show the highest enzymatic activity of the three genotypic groups. This variant has been examined in the context of estrogen-sensitive tissue biology and hormone metabolism across multiple populations.

CYP1B1 Asn453Ser (rs1800440) — a variant associated with reduced catalytic activity in some functional analyses. Women carrying the Ser allele may have somewhat lower CYP1B1 activity, modestly shifting the 2:4 ratio toward the 2-OHE2 pathway.

In combination, CYP1B1 variants that increase enzyme activity produce more 4-OHE2 — a more reactive catechol estrogen that places greater demand on Phase 2 clearance enzymes, particularly COMT and the glutathione S-transferases. The significance of any single CYP1B1 variant is best read alongside CYP1A1 activity and the Phase 2 enzyme genetics that must clear whatever 4-OHE2 is produced.

The 2-OHE2:4-OHE2 Ratio: Why the Balance Matters

Both 2-OHE2 and 4-OHE2 are catechol estrogens requiring Phase 2 inactivation. But they are not biologically equivalent, and the difference matters particularly in the context of estrogen-pathway support strategies.

Receptor activity: 4-OHE2 binds estrogen receptors with higher affinity than 2-OHE2. A higher 4-OHE2 burden maintains a stronger estrogenic signal at receptors even after estradiol has been converted through Phase 1. In women with higher CYP1B1 activity, the Phase 1 step partially sustains estrogen signaling rather than reducing it.

Quinone formation risk: Both catechol estrogens can be oxidized to semiquinones and quinones, but 4-OHE2-derived quinones (4-OHE2-Q) have greater documented reactivity with DNA bases — specifically forming depurinating adducts at adenine and guanine. The formation of these adducts depends on whether COMT methylates 4-OHE2 rapidly enough to prevent quinone formation. A woman with high CYP1B1 activity and simultaneously slow COMT (Met/Met at Val158Met) faces a higher 4-OHE2 production rate meeting a slower methylation clearance rate — a compounding effect that increases demand on glutathione-dependent detoxification as a protective backup.

COMT substrate competition: Both 2-OHE2 and 4-OHE2 are COMT substrates, but COMT has modestly higher affinity for 4-OHE2. When CYP1B1 activity elevates 4-OHE2, COMT must prioritize the more reactive substrate — which can affect how efficiently 2-OHE2 is simultaneously cleared. The interaction between CYP1B1 activity and COMT methylation capacity is a core reason the COMT Val158Met and Estrogen Clearance post should be read alongside this one.

CYP1A1 and CYP1B1 in the Context of Estrogen-Pathway Support

For women considering estrogen-pathway support through any delivery route — whether for perimenopausal symptoms, cycle-related concerns, or other reproductive health goals — CYP1A1 and CYP1B1 genetics establish the Phase 1 landscape into which additional estrogen substrate will enter. Any approach that increases circulating estradiol provides more substrate for both enzymes to act on. The ratio of those enzyme activities — determined substantially by the variants above — shapes how much of that additional substrate is routed toward 2-OHE2 versus 4-OHE2, and therefore how much clearance demand lands on Phase 2 enzymes.

A woman with high-activity CYP1B1 and slow COMT brings a Phase 1/Phase 2 mismatch to any estrogen-pathway support protocol that a provider knowing only estradiol blood levels cannot detect from bloodwork alone. This is precisely why genetic characterization of Phase 1 hydroxylation is built into the Women's Hormone pathway of the Precision Peptide Genetic Test — it maps the substrate routing before the clearance question ever arises.

CYP1A1 and CYP1B1 in the Full Women's Hormone Genetic Panel

CYP1A1 and CYP1B1 sit at the Phase 1 entry point of the estrogen metabolism cascade. Their connections to the other insights in the full panel — covered in the Complete Guide to Genetic Women's Hormone Testing:

COMT — Phase 2 downstream of both enzymes. COMT methylates the catechol estrogens CYP1A1 and CYP1B1 produce. CYP1B1-driven 4-OHE2 elevation combined with Met/Met slow COMT creates the most significant Phase 1/Phase 2 mismatch in the panel. COMT Val158Met and Estrogen Clearance covers Phase 2 methylation in full.

MTHFR — SAMe supply that COMT depends on. Impaired MTHFR-dependent SAMe production limits COMT's ability to methylate 4-OHE2 at capacity even when COMT genotype is normal. A high 4-OHE2 burden from CYP1B1 activity meeting low SAMe from MTHFR impairment stacks upstream and downstream constraints. MTHFR and Methylation: The Women's Hormone Connection covers the full methylation cascade.

GSTM1 / GSTT1 — glutathione backup clearance. When COMT cannot fully keep pace with 4-OHE2 production, GSTM1 and GSTT1 conjugate 4-OHE2-derived quinones for excretion. Null deletions in these genes eliminate that backup pathway — making CYP1B1 high-activity variants more consequential in that genetic background. GSTM1 and GSTT1: Glutathione and Hormone Detox covers this downstream protection layer.

SULT1A1 — sulfation as a parallel Phase 2 route. SULT1A1 sulfates estrogens through a pathway parallel to methylation. High-activity SULT1A1 can partially offset the clearance demand created by elevated 4-OHE2. SULT1A1 Sulfation: Estrogen Detox Genetics covers the sulfation pathway.

ESR1 / ESR2 — receptor sensitivity to the Phase 1 metabolites. Estrogen receptor variants determine how sensitively tissues respond to the 4-OHE2 that CYP1B1 produces before clearance completes. Higher ESR1 sensitivity amplifies the sustained estrogenic signal. Estrogen Receptor Genetics: ESR1 and ESR2 Variants covers receptor sensitivity.

What Your CYP1A1 and CYP1B1 Results Can and Cannot Tell You

CYP1A1 and CYP1B1 variant analysis reveals your genetic baseline for Phase 1 estrogen hydroxylation — the enzymatic tendency that routes estradiol toward 2-OHE2 or 4-OHE2. Results are not a measurement of your current catechol estrogen levels; those require specialized metabolite testing. They do not diagnose any clinical condition. And they do not predict your response to any specific estrogen-pathway compound or hormone protocol.

What they deliver is a defined Phase 1 metabolic profile: whether your estrogen hydroxylation leans toward the lower-reactivity 2-OHE2 route, the higher-reactivity 4-OHE2 route, or somewhere in between — informing how providers think about Phase 2 support priorities, monitor clearance demand, and calibrate estrogen-pathway strategies to your individual metabolic architecture. Genetics as a guide, not a guarantee — and as part of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, CYP1A1 and CYP1B1 give providers the Phase 1 routing context that shapes every downstream clearance decision.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your CYP1A1 and CYP1B1 variants and how Phase 1 estrogen metabolism fits your complete hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About CYP1A1, CYP1B1, and Estrogen Metabolism

What is the difference between CYP1A1 and CYP1B1 in estrogen metabolism?

CYP1A1 preferentially produces 2-OHE2 — a less reactive, weakly estrogenic Phase 1 estrogen metabolite. CYP1B1 preferentially produces 4-OHE2 — a more reactive, more estrogenic metabolite with higher genotoxic potential if not cleared by COMT. The Precision Peptide Genetic Test analyzes both as part of 6 Reproductive Health insights within 14 pathways, 150+ genetic insights.

Why does the CYP1B1 Leu432Val variant matter for women's hormone health?

CYP1B1 Leu432Val (rs1056836) is the most studied CYP1B1 variant in estrogen biology. The Val allele increases enzyme activity, producing more 4-OHE2 per unit of estrogen substrate. Elevated 4-OHE2 places greater demand on COMT methylation and GSTM1/GSTT1 clearance. The Precision Peptide Genetic Test analyzes CYP1B1 alongside COMT within the Reproductive Health pathway.

How do CYP1A1 and CYP1B1 variants interact with COMT genetics?

CYP1A1 and CYP1B1 determine how much 2-OHE2 and 4-OHE2 are produced; COMT methylates both for excretion. High-activity CYP1B1 paired with slow-COMT Met/Met genotype creates the most significant Phase 1/Phase 2 mismatch — more reactive 4-OHE2 produced meeting slower clearance. The Precision Peptide Genetic Test analyzes all three within 14 pathways and 150+ genetic insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.